VANDA PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.24 USD | +29.38% |
|
+22.43% | +24.17% |
| Apr. 17 | Deals of the day-Mergers and acquisitions | RE |
| Apr. 17 | Sector Update: Health Care Stocks Retreating Late Afternoon | MT |
Financials (USD)
| Sales 2022 | 254M | Sales 2023 | 193M | Capitalization | 243M |
|---|---|---|---|---|---|
| Net income 2022 | 6M | Net income 2023 | 2M | EV / Sales 2022 | -0.15 x |
| Net cash position 2022 | 456M | Net cash position 2023 | 379M | EV / Sales 2023 | -0.71 x |
| P/E ratio 2022 |
67.2
x | P/E ratio 2023 |
106
x | Employees | 203 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 94.79% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vanda Pharmaceuticals Inc.
More recommendations
More press releases
More news
| 1 day | +1.91% | ||
| 1 week | +22.43% | ||
| Current month | +27.49% | ||
| 1 month | +39.73% | ||
| 3 months | +39.36% | ||
| 6 months | +16.70% | ||
| Current year | +24.17% |
1 week
3.99
5.67
1 month
3.716.03
Current year
3.466.03
1 year
3.307.00
3 years
3.3021.86
5 years
3.3021.86
10 years
3.3033.44
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 02-10-31 | |
Kevin Moran
DFI | Director of Finance/CFO | 40 | 12-11-30 |
Scott Howell
HRO | Human Resources Officer | - | 19-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard W. Dugan
BRD | Director/Board Member | 82 | 05-11-30 |
| Chief Executive Officer | 64 | 02-10-31 | |
| Director/Board Member | 72 | 20-02-13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.34% | 29 M€ | -6.73% | ||
| 0.22% | 27 M€ | -6.65% | - | |
| 0.05% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 5.24 | +29.38% | 24,015,713 |
| 24-04-16 | 4.05 | -0.25% | 790,418 |
| 24-04-15 | 4.06 | -1.46% | 787,157 |
| 24-04-12 | 4.12 | -3.74% | 762,864 |
| 24-04-11 | 4.28 | 0.00% | 766,830 |
Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT
More quotes
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Companyâs commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
Calendar
2024-04-30
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
-
Number of Analysts
0
Last Close Price
4.05
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.17% | 233M | |
| -3.39% | 102B | |
| +2.61% | 96.09B | |
| -1.02% | 22.05B | |
| -18.14% | 20.81B | |
| -6.87% | 19.06B | |
| -40.70% | 16.05B | |
| -26.89% | 14.01B | |
| +1.12% | 13.38B | |
| +22.25% | 11.01B |
- Stock Market
- Equities
- VNDA Stock
